Rifaximin for Treatment of Hepatic Encephalopathy

被引:32
|
作者
Maclayton, Darego O. [1 ]
Eaton-Maxwell, Angie [1 ]
机构
[1] Texas So Univ, Coll Pharm & Hlth Sci, Houston, TX 77004 USA
关键词
cirrhosis; hepatic encephalopathy; rifaximin; PORTAL-SYSTEMIC ENCEPHALOPATHY; DOUBLE-BLIND; RANDOMIZED-TRIAL; ORAL RIFAXIMIN; LACTULOSE; NEOMYCIN; HOSPITALIZATIONS; PHARMACOKINETICS; MULTICENTER; MANAGEMENT;
D O I
10.1345/aph.1K436
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review the effectiveness and safety of rifaximin in the treatment of hepatic encephalopathy (HE). DATA SOURCES: MEDLINE (1990-October 2008) was searched using the terms rifaximin, rifamycins, hepatic encephalopathy, liver cirrhosis, and acute liver failure. Other sources included the bibliographies of pertinent articles as well as programs and abstracts from infectious diseases and gastrointestinal diseases meetings. STUDY SELECTION AND DATA EXTRACTION: All English-language articles identified from the search were evaluated. All primary literature that addressed the efficacy and safety of rifaximin in the treatment of HE was included in this review. DATA SYNTHESIS: HE is a complex neuropsychiatric syndrome seen in patients with liver failure. It is characterized by disturbances in consciousness and behavior, personality changes, fluctuating neurologic signs, asterixis, and electroencephalographic changes. Although the etiology of HE is unknown, the accumulation of several gut-derived toxins such as mercaptans, ammonia, and benzodiazepine has been implicated. Current treatment options for HE include agents that reduce the concentration of these toxins, such as nonabsorbable disaccharides and antibiotics. Several studies have evaluated the use of rifaximin in the treatment of HE. They include a dose-finding study, 9 open-label studies, and 4 double-blind studies comparing rifaximin with either nonabsorbable disaccharides or antibiotics. Commonly used outcomes in most of these studies were changes in portal systemic encephalopathy index and the improvement in HE grade. Despite various limitations of the studies, rifaximin showed superior efficacy compared with lactulose for the treatment of HE, similar efficacy to paromomycin, and similar or greater efficacy than neomycin. Rifaximin was found to be associated with fewer hospitalizations, fewer days of hospitalization, and lower hospitalization charges than were seen with lactulose. Rifaximin also had a better tolerance profile than the comparative agents. CONCLUSIONS: Rifaximin appears to be an effective and safe treatment option for HE. Better-designed studies are needed to characterize its efficacy in the treatment of HE.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 50 条
  • [31] RIFAXIMIN: A NONSYSTEMIC ANTIBIOTIC FOR HEPATIC ENCEPHALOPATHY
    Welliver, Mark
    GASTROENTEROLOGY NURSING, 2013, 36 (02) : 140 - 142
  • [32] Letter: the effects of rifaximin in hepatic encephalopathy
    Dai, C.
    Jiang, M.
    Sun, M. -J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (07) : 857 - 858
  • [33] Rifaximin and nonabsorbable disaccharides for hepatic encephalopathy
    Guslandi, Mario
    Cella, Alessandra
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (03) : 376 - 376
  • [34] Management of hepatic encephalopathy: Role of rifaximin
    Zeneroli, ML
    Avallone, R
    Corsi, L
    Venturini, I
    Baraldi, C
    Baraldi, M
    CHEMOTHERAPY, 2005, 51 : 90 - 95
  • [35] Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: A prospective randomized study
    Paik, YH
    Lee, KS
    Han, KH
    Song, KH
    Kim, MH
    Moon, BS
    Ahn, SH
    Lee, SJ
    Park, HJ
    Lee, DK
    Chon, CY
    Lee, SI
    Moon, YM
    YONSEI MEDICAL JOURNAL, 2005, 46 (03) : 399 - 407
  • [36] Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy
    Leevy, Carroll B.
    Phillips, James A.
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (03) : 737 - 741
  • [37] A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
    Fritz, Cassandra D. L.
    Adebajo, Corlan
    Aronsohn, Andrew
    Jensen, Donald M.
    ACG CASE REPORTS JOURNAL, 2014, 2 (01): : 42 - 44
  • [38] Rifaximin for the treatment of hepatic encephalopathy (vol 4, pg 665, 2010)
    Mullen, Kevin
    Prakash, Ravi
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 5 (01) : 133 - 134
  • [39] RIFAXIMIN FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY; A META-ANALYSIS OF RANDOMISED STUDIES
    Morgan, M. Y.
    Morris, R. W.
    GUT, 2012, 61 : A203 - A204
  • [40] Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
    Nishida, Shinya
    Hamada, Koichi
    Nishino, Noriyuki
    Fukushima, Daizo
    Koyanagi, Ryota
    Horikawa, Yoshinori
    Shiwa, Yoshiki
    Saitoh, Satoshi
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (06) : 531 - 541